Clinical Trials
23 trialsNCT03849651 2026-06-03
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT02441803 2024-02-22
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03096782 2023-10-11
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01044745 2023-09-06
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
University of Nebraska
Phase 2 Terminated
NCT01471444 2021-12-16
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 3 Completed
NCT02424968 2021-06-24
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
Stanford University
Phase 2 Completed
NCT00469014 2021-01-26
Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00822770 2020-10-14
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00566696 2020-04-14
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies
St. Jude Children's Research Hospital
Phase 2 Completed
NCT00856388 2019-11-13
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders
Roswell Park Cancer Institute
Phase NA Completed
NCT00568633 2019-09-24
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
Stanford University
Phase 3 Terminated
NCT01093586 2019-01-23
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00709592 2018-11-09
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT
Virginia Commonwealth University
Phase 2 Completed
NCT01499147 2018-11-08
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
University of Illinois at Chicago
Phase NA Completed
NCT01745913 2018-07-11
Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies
Weill Medical College of Cornell University
Phase 2 Terminated
NCT01050764 2018-06-27
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
Stanford University
Phase 1/2 Terminated
NCT00593554 2018-04-10
Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies
Indiana University
Phase 2 Terminated
NCT00303667 2017-12-28
Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Phase 1/2 Completed
NCT00617929 2017-12-28
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00691015 2017-06-28
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT01621477 2017-02-20
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT00593645 2014-09-12
Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation
Washington University School of Medicine
Phase 2 Terminated
NCT00038857 2012-08-10
Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases
M.D. Anderson Cancer Center
Phase 2 Completed